Viking Therapeutics (NASDAQ: VKTX) is operating in one of the highest-growth pharma areas around. Viking doesn't sell weight ...

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) saw unusually large options trading on Monday. Stock investors acquired 31,516 call options on the stock. This is an increase of 87% compared ...

Viking Therapeutics, Inc. (VKTX) closed the latest trading day at $23.91, indicating a -0.99% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 0.38% ...

Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zentalis Pharmaceuticals (ZNTL – Research ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20 ...

Viking Therapeutics (VKTX) announced the completion of subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of ...

Viking Therapeutics (NASDAQ: VKTX) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may ...

Is this a good time to buy shares of Viking Therapeutics, or could more of a decline be coming this year? The case for buying shares of Viking stock today Making a bullish case for Viking ...

Viking Therapeutics experienced a share price increase of 10% last week, coinciding with the announcement of a multi-year manufacturing agreement with CordenPharma for its V2735 program targeting ...

In somewhat of a surprise move, Viking Therapeutics just announced a production deal with CordenPharma, a privately held Swiss company. The move supports the commercial launch of a drug just now ...

In this article, we are going to take a look at where Viking Therapeutics Inc. (NASDAQ:VKTX) stands against other stocks that are skyrocketing today. The stock market ended mixed on Wednesday ...